This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Crestor RAPID (The Efficacy of RosuvAstatin for Korean Dyslipidemia PatIents With Diabetes) (RAPID)

This study has been completed.
Information provided by:
AstraZeneca Identifier:
First received: September 5, 2007
Last updated: March 29, 2010
Last verified: March 2010
To evaluate the efficacy of rosuvastatin in Korean dyslipidemia patients with diabetes

Dyslipidemia Diabetes

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: RAPID (Evaluating the Efficacy of RosuvAstatin for Korean Dyslipidemia PatIents With Diabetes in Real World Practice)

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Estimated Enrollment: 5000
Study Start Date: June 2007
Study Completion Date: December 2007
Primary Completion Date: August 2007 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Diabetic Mellitus patients with hypercholesteromia in Korean tertiary care centers

Inclusion Criteria:

  • Hyperlipidemia patients who are prescribed with rosuvastatin 10mg, based on clinical grounds and fulfil the following criteria

    1. Over 18 years of age
    2. Diagnosed with DM based on fasting or post-load glucose data and/or clinical assessment by the clinician

Exclusion Criteria:

  1. Patients already taking other hyperlipidemic agents
  2. Patients who do not fulfil the indication criteria for statin therapy
  3. Patients who do not have baseline and/or follow-up lipid data to verify the efficacy data
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00526552

Korea, Republic of
Research Site
Seoul, Jongro-gu, Korea, Republic of
Research Site
Seoul, Kangnam-gu, Korea, Republic of
Research Site
Seoul, Songpa-gu, Korea, Republic of
Sponsors and Collaborators
Study Director: Hyunah Caroline Choi AstraZeneca Korea
  More Information

Additional Information: Identifier: NCT00526552     History of Changes
Other Study ID Numbers: NIS-CKR-CRE-2007/3
Study First Received: September 5, 2007
Last Updated: March 29, 2010

Keywords provided by AstraZeneca:

Additional relevant MeSH terms:
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Lipid Metabolism Disorders
Rosuvastatin Calcium
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Anticholesteremic Agents
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Enzyme Inhibitors
Lipid Regulating Agents processed this record on August 17, 2017